38 related articles for article (PubMed ID: 23404099)
1. Clinical Advances and Perspectives in Targeted Radionuclide Therapy.
Lepareur N; Ramée B; Mougin-Degraef M; Bourgeois M
Pharmaceutics; 2023 Jun; 15(6):. PubMed ID: 37376181
[TBL] [Abstract][Full Text] [Related]
2. Melanin-like nanoparticles: advances in surface modification and tumour photothermal therapy.
Tian L; Li X; Ji H; Yu Q; Yang M; Guo L; Huang L; Gao W
J Nanobiotechnology; 2022 Nov; 20(1):485. PubMed ID: 36402976
[TBL] [Abstract][Full Text] [Related]
3. Targeting Melanin in Melanoma with Radionuclide Therapy.
Allen KJH; Malo ME; Jiao R; Dadachova E
Int J Mol Sci; 2022 Aug; 23(17):. PubMed ID: 36076924
[TBL] [Abstract][Full Text] [Related]
4. Translating Molecules into Imaging-The Development of New PET Tracers for Patients with Melanoma.
Vercellino L; de Jong D; Dercle L; Hosten B; Braumuller B; Das JP; Deng A; Moya-Plana A; A'Keen C; Yeh R; Merlet P; Baroudjian B; Salvatore MM; Capaccione KM
Diagnostics (Basel); 2022 Apr; 12(5):. PubMed ID: 35626272
[TBL] [Abstract][Full Text] [Related]
5. Phase I study of [
Thivat E; Rouanet J; Auzeloux P; Sas N; Jouberton E; Levesque S; Billoux T; Mansard S; Molnar I; Chanchou M; Fois G; Maigne L; Chezal JM; Miot-Noirault E; D'Incan M; Durando X; Cachin F
BMC Cancer; 2022 Apr; 22(1):417. PubMed ID: 35428211
[TBL] [Abstract][Full Text] [Related]
6. Melanin and Melanin-Functionalized Nanoparticles as Promising Tools in Cancer Research-A Review.
Marcovici I; Coricovac D; Pinzaru I; Macasoi IG; Popescu R; Chioibas R; Zupko I; Dehelean CA
Cancers (Basel); 2022 Apr; 14(7):. PubMed ID: 35406610
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of Targeted Radionuclide Therapy Using [
Akil H; Quintana M; Raymond JH; Billoux T; Benboubker V; Besse S; Auzeloux P; Delmas V; Petit V; Larue L; D'Incan M; Degoul F; Rouanet J
Cancers (Basel); 2021 Mar; 13(6):. PubMed ID: 33804655
[TBL] [Abstract][Full Text] [Related]
8. Immune checkpoint inhibitors reverse tolerogenic mechanisms induced by melanoma targeted radionuclide therapy.
Rouanet J; Benboubker V; Akil H; Hennino A; Auzeloux P; Besse S; Pereira B; Delorme S; Mansard S; D'Incan M; Degoul F; Rouzaire PO
Cancer Immunol Immunother; 2020 Oct; 69(10):2075-2088. PubMed ID: 32447411
[TBL] [Abstract][Full Text] [Related]
9. Targeted Radionuclide Therapy Decreases Melanoma Lung Invasion by Modifying Epithelial-Mesenchymal Transition-Like Mechanisms.
Akil H; Rouanet J; Viallard C; Besse S; Auzeloux P; Chezal JM; Miot-Noirault E; Quintana M; Degoul F
Transl Oncol; 2019 Nov; 12(11):1442-1452. PubMed ID: 31421458
[TBL] [Abstract][Full Text] [Related]
10. PET and SPECT imaging of melanoma: the state of the art.
Wei W; Ehlerding EB; Lan X; Luo Q; Cai W
Eur J Nucl Med Mol Imaging; 2018 Jan; 45(1):132-150. PubMed ID: 29085965
[TBL] [Abstract][Full Text] [Related]
11. Theranostic Approach for Metastatic Pigmented Melanoma Using ICF15002, a Multimodal Radiotracer for Both PET Imaging and Targeted Radionuclide Therapy.
Rbah-Vidal L; Vidal A; Billaud EM; Besse S; Ranchon-Cole I; Mishellany F; Perrot Y; Maigne L; Moins N; Guerquin-Kern JL; Degoul F; Chezal JM; Auzeloux P; Miot-Noirault E
Neoplasia; 2017 Jan; 19(1):17-27. PubMed ID: 27987437
[TBL] [Abstract][Full Text] [Related]
12. Targeting DNA repair by coDbait enhances melanoma targeted radionuclide therapy.
Viallard C; Chezal JM; Mishellany F; Ranchon-Cole I; Pereira B; Herbette A; Besse S; Boudhraa Z; Jacquemot N; Cayre A; Miot-Noirault E; Sun JS; Dutreix M; Degoul F
Oncotarget; 2016 Mar; 7(11):12927-36. PubMed ID: 26887045
[TBL] [Abstract][Full Text] [Related]
13. Synthesis and Biological Evaluation of New Quinoxaline Derivatives of ICF01012 as Melanoma-Targeting Probes.
El Aissi R; Liu J; Besse S; Canitrot D; Chavignon O; Chezal JM; Miot-Noirault E; Moreau E
ACS Med Chem Lett; 2014 May; 5(5):468-73. PubMed ID: 24900863
[TBL] [Abstract][Full Text] [Related]
14. In vivo efficacy of melanoma internal radionuclide therapy with a 131I-labelled melanin-targeting heteroarylcarboxamide molecule.
Degoul F; Borel M; Jacquemot N; Besse S; Communal Y; Mishellany F; Papon J; Penault-Llorca F; Donnarieix D; Doly M; Maigne L; Miot-Noirault E; Cayre A; Cluzel J; Moins N; Chezal JM; Bonnet M
Int J Cancer; 2013 Sep; 133(5):1042-53. PubMed ID: 23404099
[TBL] [Abstract][Full Text] [Related]
15. Targeted radionuclide therapy of melanoma: anti-tumoural efficacy studies of a new 131I labelled potential agent.
Bonnet-Duquennoy M; Papon J; Mishellany F; Labarre P; Guerquin-Kern JL; Wu TD; Gardette M; Maublant J; Penault-Llorca F; Miot-Noirault E; Cayre A; Madelmont JC; Chezal JM; Moins N
Int J Cancer; 2009 Aug; 125(3):708-16. PubMed ID: 19437532
[TBL] [Abstract][Full Text] [Related]
16. Anti-melanoma efficacy of internal radionuclide therapy in relation to melanin target distribution.
Bonnet M; Mishellany F; Papon J; Cayre A; Penault-Llorca F; Madelmont JC; Miot-Noirault E; Chezal JM; Moins N
Pigment Cell Melanoma Res; 2010 Oct; 23(5):e1-11. PubMed ID: 20444199
[TBL] [Abstract][Full Text] [Related]
17. [¹²³I]ICF01012 melanoma imaging and [¹³¹I]ICF01012 dosimetry allow adapted internal targeted radiotherapy in preclinical melanoma models.
Viallard C; Perrot Y; Boudhraa Z; Jouberton E; Miot-Noirault E; Bonnet M; Besse S; Mishellany F; Cayre A; Maigne L; Rbah-Vidal L; D'Incan M; Cachin F; Chezal JM; Degoul F
Eur J Dermatol; 2015; 25(1):29-35. PubMed ID: 25548082
[TBL] [Abstract][Full Text] [Related]
18. Targeting melanoma with 211At/131I-methylene blue: preclinical and clinical experience.
Link EM
Hybridoma; 1999 Feb; 18(1):77-82. PubMed ID: 10211792
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
